<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26071135</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2066</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Antiviral chemistry &amp; chemotherapy</Title><ISOAbbreviation>Antivir Chem Chemother</ISOAbbreviation></Journal><ArticleTitle>Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>61</EndPage><MedlinePgn>56-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2040206615589035</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Enterovirus genus of the Picornaviridae is represented by several viral pathogens that are associated with human disease, namely Poliovirus 1, Enterovirus 71 and Rhinoviruses. Enterovirus 71 has been associated with encephalitis, while Rhinoviruses are a major cause of asthma exacerbations and chronic obstructive pulmonary disease. Based on the structure of both pleconaril and pirodavir, we previously synthesized some original compounds as potential inhibitors of Rhinovirus replication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">These compounds were explored for in&#xa0;vitro antiviral potential on other human pathogenic Enteroviruses, namely Enterovirus 71 on rhabdo-myosarcoma cells, Coxsackievirus B3 on Vero cells, Poliovirus 1 and Echovirus 11 on BGM cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Activity was confirmed for compound against Rhinovirus 14. Furthermore, few compounds showed a cell-protective effect on Enterovirus 71, presented a marked improvement as compared to the reference drug pleconaril for inhibitory activity on both Enterovirus 71 and Poliovirus 1. The most striking observation was the clear cell protective effect for the set of analogues in a virus-cell-based assay for Echovirus 11 with an effective concentration (EC50) as low as 0.3&#x2009;&#xb5;M (Selectivity index or SI&#x2009;=&#x2009;483), and selectivity indexes greater than 857 (EC50&#x2009;=&#x2009;0.6&#x2009;&#xb5;M) and 1524 (EC50&#x2009;=&#x2009;0.33&#x2009;&#xb5;M).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Some of the evaluated compounds showed potent and selective antiviral activity against several enterovirus species, such as Enterovirus 71 (EV-A), Echovirus 11 (EV-B), and Poliovirus 1 (EV-C). This could be used as a starting point for the development of other pleconaril/pirodavir-like enterovirus inhibitors with broad-spectrum activity and improved effects as compared to the reference drugs.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2015.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemical and Geological Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato (CA), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Laboratory for Virology and Chemotherapy, KU Leuven - University of Leuven, Rega Institute for Medical Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabiddu</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Chemical and Geological Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato (CA), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Laboratory for Virology and Chemotherapy, KU Leuven - University of Leuven, Rega Institute for Medical Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Laboratory for Virology and Chemotherapy, KU Leuven - University of Leuven, Rega Institute for Medical Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pompei</LastName><ForeName>Raffaello</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy rpompei@unica.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Chem Chemother</MedlineTA><NlmUniqueID>9009212</NlmUniqueID><ISSNLinking>0956-3202</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical><Chemical><RegistryNumber>BML697718K</RegistryNumber><NameOfSubstance UI="C074589">pirodavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">early stage</Keyword><Keyword MajorTopicYN="N">pirodavir</Keyword><Keyword MajorTopicYN="N">pleconaril</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26071135</ArticleId><ArticleId IdType="pmc">PMC5890516</ArticleId><ArticleId IdType="doi">10.1177/2040206615589035</ArticleId><ArticleId IdType="pii">2040206615589035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol 2005; 11: 424&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltola V, Waris M, Osterback R, et al. Clinical effects of rhinovirus infections. J Clin Virol 2008; 43: 411&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">18835215</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wu S, Xiong Y, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One 2014; 9: e96051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002479</ArticleId><ArticleId IdType="pubmed">24776922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183: 734&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081284</ArticleId><ArticleId IdType="pubmed">20889904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 2010; 125: 1178&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172767</ArticleId><ArticleId IdType="pubmed">20513517</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries K, Dewindt B, Snoeks J, et al. In&#xa0;vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992; 36: 100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 2003; 23: 339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7168037</ArticleId><ArticleId IdType="pubmed">12627933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36: 1523&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis 2002; 2: 264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992; 36: 727&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189373</ArticleId><ArticleId IdType="pubmed">1503435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39: 290&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162529</ArticleId><ArticleId IdType="pubmed">7726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S. The discovery and development of vapendavir: a potent and selective antiviral with potential for the treatment of picornavirus associated diseases. In: Europic 2014, 18th international Picornavirus meeting, 9&#x2013;14 March 2014, Blonkenberge, Belgium.</Citation></Reference><Reference><Citation>Bernard AM, Cabiddu MG, Demontis MS, et al. Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses. Bioorg Med Chem 2014; 22: 4061&#x2013;4066.</Citation><ArticleIdList><ArticleId IdType="pubmed">24973816</ArticleId></ArticleIdList></Reference><Reference><Citation>Laconi S, Madeddu MA, Pompei R. Study of the biological activity of novel synthetic compounds with antiviral properties against human rhinoviruses. Molecules 2011; 16: 3479&#x2013;3487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6263271</ArticleId><ArticleId IdType="pubmed">21522081</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick A, Macadam AJ, Dunn G, et al. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 1995; 69: 7601&#x2013;7605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189699</ArticleId><ArticleId IdType="pubmed">7494267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Notebaart RA, et al. A proline-rich region in the Coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol 2005; 79: 5163&#x2013;5173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069528</ArticleId><ArticleId IdType="pubmed">15795300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson JM, Coyne CB. Picornavirus entry. Adv Exp Med Biol 2013; 790: 24&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23884584</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>